Vaccines (Nov 2023)

Antibody Profiling of Microbial Antigens in the Blood of COVID-19 mRNA Vaccine Recipients Using Microbial Protein Microarrays

  • Hiroaki Saito,
  • Hiroki Yoshimura,
  • Makoto Yoshida,
  • Yuta Tani,
  • Moe Kawashima,
  • Taiga Uchiyama,
  • Tianchen Zhao,
  • Chika Yamamoto,
  • Yurie Kobashi,
  • Toyoaki Sawano,
  • Seiya Imoto,
  • Hyeongki Park,
  • Naotoshi Nakamura,
  • Shingo Iwami,
  • Yudai Kaneko,
  • Aya Nakayama,
  • Tatsuhiko Kodama,
  • Masatoshi Wakui,
  • Takeshi Kawamura,
  • Masaharu Tsubokura

DOI
https://doi.org/10.3390/vaccines11111694
Journal volume & issue
Vol. 11, no. 11
p. 1694

Abstract

Read online

Although studies have demonstrated that infections with various viruses, bacteria, and parasites can modulate the immune system, no study has investigated changes in antibodies against microbial antigens after the COVID-19 mRNA vaccination. IgG antibodies against microbial antigens in the blood of vaccinees were comprehensively analyzed using microbial protein microarrays that carried approximately 5000 microbe-derived proteins. Changes in antibodies against microbial antigens were scrutinized in healthy participants enrolled in the Fukushima Vaccination Community Survey conducted in Fukushima Prefecture, Japan, after their second and third COVID-19 mRNA vaccinations. Antibody profiling of six groups stratified by antibody titer and the remaining neutralizing antibodies was also performed to study the dynamics of neutralizing antibodies against SARS-CoV-2 and the changes in antibodies against microbial antigens. The results showed that changes in antibodies against microbial antigens other than SARS-CoV-2 antigens were extremely limited after COVID-19 vaccination. In addition, antibodies against a staphylococcal complement inhibitor have been identified as microbial antigens that are associated with increased levels of neutralizing antibodies against SARS-CoV-2. These antibodies may be a predictor of the maintenance of neutralizing antibodies following the administration of a COVID-19 mRNA vaccine.

Keywords